Please login to the form below

UDG Healthcare appoints Jez Moulding as Group Chief Operating Officer and Executive Vice President of Ashfield

UDG Healthcare plc (“the Group”), a leading international healthcare services provider, is pleased to announce the appointment of Jez Moulding as Chief Operating Officer (“COO”) of UDG Healthcare plc and Executive Vice President of Ashfield with effect from 2 May 2017

Jez will oversee the Ashfield Division globally and will also have responsibility for Group IT, Quality, Compliance, Strategy and Communications as part of his role as COO of UDG Healthcare plc. The Sharp and Aquilant divisions will continue to report directly to Brendan McAtamney, CEO of UDG Healthcare plc.

Jez brings extensive international pharmaceutical experience to UDG having spent 18 years at Sanofi, holding numerous senior leadership positions across the globe, in the UK, France, South Africa, Korea, Australia, Japan and the US. In his most recent role as Senior Vice President and North America Region Head for Diabetes and Cardiovascular, he was responsible for 3,500 employees and sales of over $5 billion. Prior to joining Sanofi in 1999, Jez held a variety of positions at Astra Pharmaceuticals and Winchester Pharmaceuticals in the UK.

Brendan McAtamney, CEO of UDG Healthcare, said: “We are delighted to welcome Jez to UDG Healthcare and to Ashfield. He has extensive leadership experience in the pharmaceutical sector within our key global markets. His most recent experience leading the Sanofi North American business will be extremely valuable to us as we continue to develop our Ashfield US business and expand the Group internationally.”

Jez Moulding, incoming COO of UDG Healthcare plc and Executive Vice President of Ashfield, said: “I am thrilled to be joining such a fast growing, dynamic team in Ashfield and UDG Healthcare. Ashfield has grown over many years and is a market leader in commercialisation services to global pharmaceutical clients. I look forward to building on this strong platform and driving further international expansion across the Group.”

As previously announced, Chris Corbin will transition to the role of Chairman of Ashfield and continue as a Non-Executive Director of UDG Healthcare.

For more information on Ashfield please click here, and for more information on UDG Healthcare please click here

13th April 2017


Company Details


Contact Website

Ashfield House
Resolution Road
Ashby de la Zouch
LE65 1HW

Latest content on this profile

Ashfield wins Best Newcomer at the Pf Awards 2018
We are thrilled to announce that Zuchaela Smylie, from Ashfield, won Best Newcomer at the 2018 Pf Awards, the largest pharmaceutical sales awards in the UK. The awards ceremony took place on Thursday, 9 March at The Lancaster Hotel in London.
“It is evident that meeting face-to-face is still highly valued in the digital age”
Attending a scientific congress or meeting overtakes professional journals and publications as the educational channel of choice for Healthcare Professionals – according to findings of new study
Ashfield to present at the Orphan Drugs for Rare Diseases Summit
Ashfield has a breadth of experience with orphan drugs and we are passionate about helping to improve the lives of people living with rare diseases. We are delighted to be sponsoring and presenting at the ‘Orphan Drugs for Rare Diseases’ event 22-23 March in Berlin.
Addressing the biggest challenges for rare disease communities
Each year, Rare Disease Day takes place worldwide on the last day in February. The main objective of Rare Disease Day is to raise awareness amongst the general public, the healthcare industry and decision-makers about rare diseases and their impact on patients' lives.
Humanise is our strategic approach to healthcare communications. It’s based on the need to understand. It looks at the emotions that make us human. It examines the feelings we have as individuals. It defines the behaviours we show as people.
Ashfield launches new commercial model to improve ROI
Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, has announced the launch of a pioneering new commercial model called The Ashfield Solution.